ATHA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 22.10%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $40,230.90

Athira Pharma Insider Trading History Chart

Athira Pharma Share Price & Price History

^$3.89

▲ +0.04 (1.04%)

As of 12/4/2025 04:59 PM ET

Days: 30 | 90 | 365

Athira Pharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/1/2025	Mark James Litton	CEO	Sell	2,512	$2.90	$7,284.80	32,580
7/1/2025	Mark Worthington	General Counsel	Sell	852	$2.90	$2,470.80	11,187
7/1/2025	Martin Javier San	Insider	Sell	1,084	$2.90	$3,143.60	7,166
7/1/2025	Robert Renninger	SVP	Sell	289	$2.90	$838.10	10,918
1/2/2025	Mark James Litton	CEO	Sell	2,510	$5.60	$14,056.00	24,259
1/2/2025	Mark Worthington	General Counsel	Sell	851	$5.60	$4,765.60	8,373
1/2/2025	Martin Javier San	Insider	Sell	1,082	$5.60	$6,059.20	3,584
1/2/2025	Robert Renninger	VP	Sell	288	$5.60	$1,612.80	8,972
9/5/2024	Andrew Gengos	CFO	Sell	127	$5.70	$723.90	9,753
9/5/2024	Mark James Litton	CEO	Sell	503	$5.70	$2,867.10	15,936
9/5/2024	Rachel Lenington	COO	Sell	252	$5.70	$1,436.40	2,087
6/24/2024	Kelly A Romano	Director	Buy	2,740	$24.20	$66,308.00	8,071
6/21/2024	Kelly A Romano	Director	Buy	1,500	$22.60	$33,900.00	5,331
1/5/2024	Andrew Gengos	Insider	Sell	120	$29.10	$3,492.00	8,380
1/5/2024	Mark James Litton	CEO	Sell	482	$29.10	$14,026.20	14,439
1/5/2024	Mark Worthington	General Counsel	Sell	241	$29.10	$7,013.10	3,445
12/29/2023	Perceptive Advisors Llc	Director	Buy	16,395	$23.80	$390,201.00	540,296
12/27/2023	Perceptive Advisors Llc	Director	Buy	3,213	$22.80	$73,256.40	482,941
6/7/2023	Andrew Gengos	Insider	Buy	1,500	$34.30	$51,450.00	8,001
6/5/2023	Andrew Gengos	Insider	Buy	4,500	$30.00	$135,000.00	6,501
6/2/2023	Andrew Gengos	Insider	Buy	2,001	$28.20	$56,428.20	2,001
3/29/2023	James A Johnson	Director	Buy	500	$24.00	$12,000.00	500
12/28/2022	Glenna Mileson	CFO	Buy	5,000	$28.50	$142,500.00	15,993
12/2/2022	Kelly A Romano	Director	Buy	3,000	$32.90	$98,700.00	3,831

SEC Filings (Institutional Ownership Changes) for Athira Pharma (NASDAQ:ATHA)

57.12% of Athira Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Athira Pharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/17/2025	Susquehanna International Group LLP	20,986	$87K	0.0%	-73.9%	0.533%
11/17/2025	Laird Norton Wetherby Trust Company LLC	10,088	$42K	0.0%	-92.1%	0.256%
11/17/2025	Focus Partners Wealth	8,415	$35K	0.0%	N/A	0.214%
11/17/2025	Citadel Advisors LLC	33,987	$0.14M	0.0%	-85.5%	0.863%
11/17/2025	Bank of America Corp DE	32,614	$0.14M	0.0%	-92.2%	0.828%
11/12/2025	Propel Bio Management LLC	149,279	$0.62M	0.6%	-90.0%	3.789%
11/10/2025	BML Capital Management LLC	323,066	$1.34M	1.0%	-90.0%	8.191%
10/20/2025	Simplify Asset Management Inc.	149,279	$0.62M	0.0%	-90.0%	3.789%
8/14/2025	Qube Research & Technologies Ltd	192,684	$58K	0.0%	-12.8%	0.489%
8/11/2025	BML Capital Management LLC	3,230,667	$0.98M	0.7%	+0.9%	8.275%
5/12/2025	Bristlecone Advisors LLC	252,200	$72K	0.0%	-25.3%	0.646%
5/7/2025	BML Capital Management LLC	3,200,667	$0.91M	0.7%	+15.3%	8.198%
2/17/2025	Two Sigma Advisers LP	253,300	$0.15M	0.0%	-25.0%	0.655%
2/13/2025	Renaissance Technologies LLC	207,300	$0.12M	0.0%	-54.2%	0.536%
2/7/2025	BML Capital Management LLC	2,775,885	$1.63M	1.0%	N/A	7.178%
11/5/2024	GSA Capital Partners LLP	397,111	$0.18M	0.0%	+909.8%	1.033%
10/24/2024	Bristlecone Advisors LLC	337,506	$0.15M	0.0%	+295.6%	0.881%
8/16/2024	Invst LLC	27,000	$68K	0.0%	N/A	0.070%
8/16/2024	Forefront Analytics LLC	46,595	$0.12M	0.1%	+126.0%	0.122%
8/12/2024	XTX Topco Ltd	22,695	$60K	0.0%	N/A	0.059%
8/9/2024	Renaissance Technologies LLC	271,488	$0.72M	0.0%	+3.5%	0.708%
8/9/2024	Dimensional Fund Advisors LP	550,353	$1.46M	0.0%	+25.5%	1.436%
8/8/2024	American Century Companies Inc.	38,940	$0.10M	0.0%	+9.4%	0.102%
8/6/2024	Acadian Asset Management LLC	318,090	$0.84M	0.0%	-42.2%	0.830%
7/31/2024	Rothschild Investment LLC	12,900	$34K	0.0%	N/A	0.034%
5/16/2024	Jacobs Levy Equity Management Inc.	497,475	$1.36M	0.0%	+84.1%	1.298%
5/10/2024	Acadian Asset Management LLC	549,938	$1.51M	0.0%	+281.5%	1.435%
5/10/2024	Vanguard Group Inc.	1,634,433	$4.48M	0.0%	-3.8%	4.264%
5/3/2024	GSA Capital Partners LLP	176,230	$0.48M	0.0%	-41.4%	0.460%
4/23/2024	BML Capital Management LLC	900,000	$2.47M	1.6%	-38.1%	2.348%
4/18/2024	Mirador Capital Partners LP	20,660	$57K	0.0%	N/A	0.054%
2/26/2024	Perceptive Advisors LLC	5,402,964	$13.13M	0.3%	+12.6%	14.096%
2/15/2024	Forefront Analytics LLC	29,765	$72K	0.0%	+43.0%	0.078%
2/6/2024	Private Advisor Group LLC	12,975	$32K	0.0%	N/A	0.034%
1/30/2024	BML Capital Management LLC	1,454,362	$3.53M	2.7%	-14.7%	3.821%
1/29/2024	Clarius Group LLC	53,551	$0.13M	0.0%	+35.8%	0.141%
11/15/2023	Laird Norton Trust Company LLC	178,709	$0.36M	0.0%	+21.3%	0.470%
11/14/2023	Nan Fung Group Holdings Ltd	180,000	$0.36M	0.3%	+1,429.4%	0.473%
11/13/2023	Acadian Asset Management LLC	139,542	$0.28M	0.0%	-43.0%	0.367%
11/7/2023	Barclays PLC	435,841	$0.88M	0.0%	+99.1%	1.145%
10/27/2023	Marquette Asset Management LLC	30,783	$62K	0.0%	N/A	0.081%
10/27/2023	Acuitas Investments LLC	149,600	$0.30M	0.2%	N/A	0.393%
10/23/2023	BML Capital Management LLC	1,704,362	$3.44M	3.2%	-8.6%	4.478%
10/19/2023	Clarius Group LLC	39,427	$80K	0.0%	N/A	0.104%
8/14/2023	Potomac Capital Management Inc.	74,585	$0.22M	0.2%	-6.8%	0.196%
8/14/2023	Prelude Capital Management LLC	28,722	$85K	0.0%	-33.1%	0.075%
8/11/2023	Nan Fung Group Holdings Ltd	11,769	$35K	0.0%	N/A	0.031%
8/7/2023	Acadian Asset Management LLC	244,819	$0.72M	0.0%	-33.3%	0.645%
7/31/2023	Brighton Jones LLC	32,200	$95K	0.0%	N/A	0.085%
6/1/2023	Prelude Capital Management LLC	42,957	$0.11M	0.0%	-31.5%	0.113%
5/16/2023	Baker BROS. Advisors LP	2,350,355	$5.88M	0.0%	+25.0%	6.194%
5/11/2023	Acadian Asset Management LLC	366,915	$0.92M	0.0%	+176.9%	0.967%
5/11/2023	Cornercap Investment Counsel Inc.	75,253	$0.19M	0.0%	N/A	0.198%
5/11/2023	Bristlecone Advisors LLC	85,306	$0.21M	0.0%	-87.8%	0.225%
5/10/2023	Simplify Asset Management Inc.	1,390,148	$3.48M	0.5%	N/A	3.664%
5/8/2023	Federated Hermes Inc.	10,581	$26K	0.0%	+60.6%	0.028%
5/8/2023	Bailard Inc.	33,894	$85K	0.0%	-24.8%	0.089%
5/4/2023	Barclays PLC	236,118	$0.59M	0.0%	+13.5%	0.622%
5/2/2023	Sargent Investment Group LLC	20,272	$51K	0.0%	+34.1%	0.053%
4/28/2023	SG Americas Securities LLC	19,512	$49K	0.0%	+63.6%	0.051%
4/17/2023	Clarius Group LLC	38,000	$95K	0.0%	+15.8%	0.100%
4/14/2023	BML Capital Management LLC	1,864,907	$4.66M	4.0%	+160.9%	4.915%
2/15/2023	Tang Capital Management LLC	485,234	$1.54M	0.2%	N/A	1.283%
2/14/2023	RA Capital Management L.P.	1,881,300	$5.96M	0.1%	+0.2%	4.973%
2/14/2023	Bristlecone Advisors LLC	696,629	$2.21M	0.3%	-0.6%	1.841%
2/14/2023	Pura Vida Investments LLC	77,700	$0.25M	0.0%	-44.5%	0.205%
2/13/2023	Forefront Analytics LLC	22,350	$71K	0.0%	N/A	0.059%
2/13/2023	BML Capital Management LLC	714,763	$2.27M	2.2%	N/A	1.889%
2/13/2023	GSA Capital Partners LLP	270,989	$0.86M	0.1%	+59.9%	0.716%
2/2/2023	Bailard Inc.	45,094	$0.14M	0.0%	N/A	0.119%
1/25/2023	Lindbrook Capital LLC	11,407	$36K	0.0%	-32.6%	0.030%
1/19/2023	Rothschild Investment Corp IL	31,100	$99K	0.0%	N/A	0.082%
11/15/2022	Pathstone Family Office LLC	1,815,540	$5.39M	0.1%	+7.5%	4.799%
11/15/2022	Pura Vida Investments LLC	139,924	$0.42M	0.0%	-47.8%	0.370%
11/14/2022	Tudor Investment Corp Et Al	69,770	$0.21M	0.0%	+66.1%	0.184%
11/3/2022	Barclays PLC	166,768	$0.50M	0.0%	+185.9%	0.441%
11/2/2022	Rockefeller Capital Management L.P.	30,100	$89K	0.0%	+198.0%	0.080%
10/27/2022	Sargent Investment Group LLC	14,932	$47K	0.0%	+45.3%	0.039%
10/24/2022	Clear Creek Financial Management LLC	10,000	$30K	0.0%	-24.7%	0.026%
8/16/2022	Pura Vida Investments LLC	268,131	$0.82M	0.0%	-21.0%	0.712%
8/8/2022	Simon Quick Advisors LLC	20,538	$78K	0.0%	N/A	0.055%
8/3/2022	Laird Norton Trust Company LLC	120,000	$0.37M	0.0%	+50.0%	0.319%
7/29/2022	SG Americas Securities LLC	12,504	$38K	0.0%	N/A	0.033%
7/26/2022	Sargent Investment Group LLC	10,280	$31K	0.0%	N/A	0.027%
7/25/2022	Bristlecone Advisors LLC	700,926	$2.14M	0.3%	-8.0%	1.862%
7/13/2022	Private Advisor Group LLC	14,475	$44K	0.0%	N/A	0.038%
6/30/2022	Amalgamated Bank	3,899	$53K	0.0%	N/A	0.010%
5/27/2022	Walleye Capital LLC	105,723	$1.43M	0.0%	N/A	0.281%
5/12/2022	Monashee Investment Management LLC	100,000	$1.35M	0.4%	N/A	0.266%
4/29/2022	Nisa Investment Advisors LLC	1,936	$26K	0.0%	+720.3%	0.005%
4/25/2022	Tradewinds Capital Management LLC	8,517	$0.12M	0.0%	N/A	0.023%
4/21/2022	Zurcher Kantonalbank Zurich Cantonalbank	2,379	$32K	0.0%	N/A	0.006%
4/21/2022	Lindbrook Capital LLC	24,173	$0.33M	0.1%	+4.1%	0.064%
4/20/2022	Belvedere Trading LLC	51,098	$0.59M	0.0%	-10.8%	0.136%
2/25/2022	AlphaCentric Advisors LLC	20,538	$0.27M	0.1%	N/A	0.055%
2/16/2022	Wasatch Advisors Inc.	1,242,423	$16.19M	0.1%	+38.6%	3.326%
2/14/2022	Virtus ETF Advisers LLC	12,249	$0.16M	0.1%	+11.8%	0.033%
2/14/2022	Point72 Asset Management L.P.	75,000	$0.98M	0.0%	N/A	0.201%
2/14/2022	Journey Strategic Wealth LLC	20,538	$0.27M	0.0%	N/A	0.055%
2/11/2022	Pentwater Capital Management LP	40,000	$0.52M	0.0%	-66.7%	0.107%

Data available starting January 2016

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Today's Range

Now: $3.89

$3.81

$3.97

50 Day Range

MA: $4.18

$3.62

$4.76

52 Week Range

Now: $3.89

$2.20

$6.68

Volume

8,369 shs

Average Volume

24,874 shs

Market Capitalization

$15.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.95

Who are the company insiders with the largest holdings of Athira Pharma?: Athira Pharma's top insider shareholders include:
Perceptive Advisors Llc (Director)
Mark James Litton (CEO)
Mark Worthington (General Counsel)
Robert Renninger (SVP)
Andrew Gengos (CFO)
Robert Renninger (VP)
Andrew Gengos (Insider)
Kelly A Romano (Director)
Martin Javier San (Insider)
Rachel Lenington (COO)
Learn More about top insider investors at Athira Pharma.
Who are the major institutional investors of Athira Pharma?: Athira Pharma's top institutional investors include:
BML Capital Management LLC — 8.19%
Propel Bio Management LLC — 3.79%
Simplify Asset Management Inc. — 3.79%
Citadel Advisors LLC — 0.86%
Bank of America Corp DE — 0.83%
Susquehanna International Group LLP — 0.53%
Learn More about top institutional investors of Athira Pharma stock.
Which major investors are selling Athira Pharma stock?: During the previous quarter, ATHA stock was sold by these institutional investors:
BML Capital Management LLC
Simplify Asset Management Inc.
Propel Bio Management LLC
Bank of America Corp DE
Citadel Advisors LLC
Laird Norton Wetherby Trust Company LLC
Susquehanna International Group LLP
Within the last year, company insiders that have sold Athira Pharma company stock include:
Perceptive Advisors Llc (Director)
Mark James Litton (CEO)
Mark Worthington (General Counsel)
Robert Renninger (SVP)
Andrew Gengos (CFO)
Learn More investors selling Athira Pharma stock.
Which major investors are buying Athira Pharma stock?: During the last quarter, ATHA stock was acquired by institutional investors including:
Focus Partners Wealth
During the previous year, these company insiders have bought Athira Pharma stock:
Perceptive Advisors Llc (Director)
Mark James Litton (CEO)
Learn More investors buying Athira Pharma stock.